197 related articles for article (PubMed ID: 30847025)
1. Circulating miRNAs as a marker of metastatic disease and prognostic factor in metastatic breast cancer.
Papadaki C; Stoupis G; Tsalikis L; Monastirioti A; Papadaki M; Maliotis N; Stratigos M; Mastrostamatis G; Mavroudis D; Agelaki S
Oncotarget; 2019 Jan; 10(9):966-981. PubMed ID: 30847025
[TBL] [Abstract][Full Text] [Related]
2. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
Papadaki C; Stratigos M; Markakis G; Spiliotaki M; Mastrostamatis G; Nikolaou C; Mavroudis D; Agelaki S
Breast Cancer Res; 2018 Jul; 20(1):72. PubMed ID: 29996899
[TBL] [Abstract][Full Text] [Related]
3. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer.
Madhavan D; Zucknick M; Wallwiener M; Cuk K; Modugno C; Scharpff M; Schott S; Heil J; Turchinovich A; Yang R; Benner A; Riethdorf S; Trumpp A; Sohn C; Pantel K; Schneeweiss A; Burwinkel B
Clin Cancer Res; 2012 Nov; 18(21):5972-82. PubMed ID: 22952344
[TBL] [Abstract][Full Text] [Related]
4. Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer.
Tan W; Liang G; Xie X; Jiang W; Tan L; Sanders AJ; Liu Z; Ling Y; Zhong W; Tian Z; Lin W; Gong C
Oncologist; 2019 Nov; 24(11):e1044-e1054. PubMed ID: 31300482
[TBL] [Abstract][Full Text] [Related]
5. Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer.
Fischer C; Deutsch TM; Feisst M; Rippinger N; Riedel F; Hartkopf AD; Brucker SY; Domschke C; Fremd C; Michel L; Burwinkel B; Schneeweiss A; Turchinovich A; Wallwiener M
Arch Gynecol Obstet; 2022 Sep; 306(3):875-885. PubMed ID: 35237856
[TBL] [Abstract][Full Text] [Related]
6. MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer.
Thomopoulou K; Papadaki C; Monastirioti A; Koronakis G; Mala A; Kalapanida D; Mavroudis D; Agelaki S
Front Mol Biosci; 2021; 8():668534. PubMed ID: 34179081
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer.
Meng X; Müller V; Milde-Langosch K; Trillsch F; Pantel K; Schwarzenbach H
Oncotarget; 2016 Mar; 7(13):16923-35. PubMed ID: 26943577
[TBL] [Abstract][Full Text] [Related]
8. Circulating miRNAs with prognostic value in metastatic breast cancer and for early detection of metastasis.
Madhavan D; Peng C; Wallwiener M; Zucknick M; Nees J; Schott S; Rudolph A; Riethdorf S; Trumpp A; Pantel K; Sohn C; Chang-Claude J; Schneeweiss A; Burwinkel B
Carcinogenesis; 2016 May; 37(5):461-70. PubMed ID: 26785733
[TBL] [Abstract][Full Text] [Related]
9. Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment.
Fischer C; Turchinovich A; Feisst M; Riedel F; Haßdenteufel K; Scharli P; Hartkopf AD; Brucker SY; Michel L; Burwinkel B; Schneeweiss A; Wallwiener M; Deutsch TM
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076930
[TBL] [Abstract][Full Text] [Related]
10. Potential of Exosomal microRNA-200b as Liquid Biopsy Marker in Pancreatic Ductal Adenocarcinoma.
Reese M; Flammang I; Yang Z; Dhayat SA
Cancers (Basel); 2020 Jan; 12(1):. PubMed ID: 31941049
[TBL] [Abstract][Full Text] [Related]
11. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer.
Toiyama Y; Hur K; Tanaka K; Inoue Y; Kusunoki M; Boland CR; Goel A
Ann Surg; 2014 Apr; 259(4):735-43. PubMed ID: 23982750
[TBL] [Abstract][Full Text] [Related]
12. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
14. The miR-200 family as prognostic markers in clear cell renal cell carcinoma.
Saleeb R; Kim SS; Ding Q; Scorilas A; Lin S; Khella HW; Boulos C; Ibrahim G; Yousef GM
Urol Oncol; 2019 Dec; 37(12):955-963. PubMed ID: 31635993
[TBL] [Abstract][Full Text] [Related]
15. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer.
Valladares-Ayerbes M; Reboredo M; Medina-Villaamil V; Iglesias-Díaz P; Lorenzo-Patiño MJ; Haz M; Santamarina I; Blanco M; Fernández-Tajes J; Quindós M; Carral A; Figueroa A; Antón-Aparicio LM; Calvo L
J Transl Med; 2012 Sep; 10():186. PubMed ID: 22954417
[TBL] [Abstract][Full Text] [Related]
16. Circulating miR-23b-3p, miR-145-5p and miR-200b-3p are potential biomarkers to monitor acute pain associated with laminitis in horses.
Lecchi C; Dalla Costa E; Lebelt D; Ferrante V; Canali E; Ceciliani F; Stucke D; Minero M
Animal; 2018 Feb; 12(2):366-375. PubMed ID: 28689512
[TBL] [Abstract][Full Text] [Related]
17. Tissue miR-200c-3p and circulating miR-1290 as potential prognostic biomarkers for colorectal cancer.
Kang E; Jung SC; Nam SK; Park Y; Seo SH; Park KU; Oh HK; Kim DW; Kang SB; Lee HS
Sci Rep; 2022 Feb; 12(1):2295. PubMed ID: 35145164
[TBL] [Abstract][Full Text] [Related]
18. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
19. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer.
McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ
BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182
[TBL] [Abstract][Full Text] [Related]
20. Plasma-Based microRNA Expression Analysis in Advanced Stage NSCLC Patients Treated with Nivolumab.
Monastirioti A; Papadaki C; Kalapanida D; Rounis K; Michaelidou K; Papadaki MA; Mavroudis D; Agelaki S
Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
